Marker Therapeutics (MRKR) announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company’s Board of Directors, effective November 1, 2025. Most recently, Penkus Corzo served as President and Chief Operating Officer at bit.bio.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRKR:
- Marker Therapeutics’ Innovative Approach in AML and MDS Treatment: A Study Update
- Marker Therapeutics’ MT-601 Study: A Promising Step in Lymphoma Treatment
- Marker Therapeutics Advances Off-the-Shelf T Cell Therapy with First Patient Treatment
- Marker Therapeutics announces first patient treated in off-the-shelf program